⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23653869 | 1.00 | — | — | |
| SCHEMBL1190350 | 1.00 | — | — | |
| SCHEMBL1189061 | 1.00 | — | — | |
| SCHEMBL1189067 | 1.00 | — | — | |
| SCHEMBL1189064 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL31242553 | 0.97 | FUCA1 (0.37) | — | |
| Hydrochloric Acid SCHEMBL1188829 | 0.97 | FUCA1 (0.37) | — | |
| SCHEMBL1189125 | 0.82 | CCR5 (0.35) | — | |
| SCHEMBL25692937 | 0.79 | — | — | |
| SCHEMBL24018543 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601282-B1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-20200339603-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10662203-B2 | Pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-9957274-B2 | Indane inhibitors of EED and methods of their use | ABBVIE INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170320880-A1 | INDANE INHIBITORS OF EED AND METHODS OF THEIR USE | ABBVIE INC. | 2017-11-09 | — | — | US | disclosed |
| US-9505755-B2 | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5A receptor modulators | NOVARTIS AG (CH) | 2016-11-29 | — | — | US | disclosed |
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20140349995-A1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-8846656-B2 | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2217226-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |